Olatoyosi Odenike to Neoplasms
This is a "connection" page, showing publications Olatoyosi Odenike has written about Neoplasms.
Connection Strength
0.597
-
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
Score: 0.082
-
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 11; 62:101128.
Score: 0.081
-
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023 07; 60:101072.
Score: 0.078
-
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 12; 36(12):2934-2938.
Score: 0.076
-
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 12; 36(12):2939-2946.
Score: 0.076
-
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
Score: 0.068
-
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638.
Score: 0.057
-
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
Score: 0.044
-
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109.
Score: 0.036